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Abstract
Background: The purpose of this study was to compare the value and evaluate the validity of non-invasive
methods for the detection of vascular stiffness in never-treated individuals with metabolic syndrome (MetS).
Methods: A total of 59 subjects (mean age, 60 ± 12 years; male:female = 35:24) were enrolled in the study and
were categorized into the positive MetS (MetS[+]: N = 32) and negative group (MetS[−]: N = 27), according to
the parameters set by the National Cholesterol Education Program’s Adult Treatment Panel III. Pulse wave
velocity (PWV) of the aorta, arm, and leg, Framingham risk score (FRS), ankle-brachial index (ABI), and carotid
intima-media thickness (IMT) for vascular aging were measured for the two groups.
Results: Aortic PWV (PWVaor) was significantly higher in MetS(+) than MetS(−) group (7.0 ± 1.4 m/s vs. 8.4 ± 1.6 m/s, p
< 0.01), while ABI was significantly lower in MetS(+) than MetS(−) group (1.2 ± 0.1 vs. 1.1 ± 0.2, p = 0.03), respectively.
FRS was significantly higher in MetS(+) than MetS(−) group (11 ± 5 vs. 14 ± 4, p = 0.05). The both mean IMT was higher
in MetS(+) than MetS(−) group (right: 0.94 ± 0.20 mm vs. 0.81 ± 0.20 mm, p = 0.03; left: 0.93 ± 0.20 mm vs. 0.79 ± 0.
20 mm, p = 0.03, respectively). For predicting the probability of the presence of MetS, PWVaor was an independent tool
(p = 0.04; odds ratio, 1.88; 95% confidence interval, 1.03 to 3.42) and a cut-off value of PWVaor of 7.4 m/s showed a
sensitivity of 66.7% and a specificity of 47.6%.
Conclusions: We suggest that PWVaor, combined with traditional tools, can play an important role as a
complementary or alternative tool for the detection of vascular stiffness in never-treated individuals with MetS.
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Background
Metabolic syndrome (MetS), characterized by a combin-
ation of several cardiovascular and metabolic risk
factors including central obesity, dyslipidemia, elevated
blood pressure, and impaired glucose tolerance [1, 2], is
a worldwide health problem associated with both
subclinical atherosclerosis and an increased risk of
cardiovascular events [3]. It is well established that
MetS not only is an accelerator of central arterial
aging but also an independent predictor of cardiovas-
cular events in older subjects [4, 5].
There are several tools for the measurement of the
relationship between cardiovascular risk factors and
vascular aging, including Framingham risk score (FRS)
[5], which estimates 10-year risk of coronary heart
disease (CHD); ankle-brachial index (ABI) [6, 7], which
is used to assess and evaluate the presence of peripheral
arterial disease (PAD) of the lower extremities; pulse
wave velocity (PWV), pulse pressure (PP), and augmen-
tation index (AIx), which reflect systemic arterial stiff-
ness are significantly and independently associated with
both target organ damage and increased risk for cardio-
vascular morbidity and mortality; subendocardial viabil-
ity ratio (SEVR), which estimates myocardial perfusion
relative to cardiac workload; ejection duration (ED),
which reflects cardiac function by assessing the duration
of left ventricular systolic ejection (systolic time interval
in milliseconds) [7–9]; and intima-media thickness
(IMT) of carotid artery [10–12].* Correspondence: younhj@catholic.ac.krDivision of Cardiology, Department of Internal Medicine, Seoul St. Mary’s
Hospital, The Catholic University of Korea College of Medicine, #505
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The purpose of this study was to compare the value
and evaluate the validity of non-invasive methods, in-
cluding FRS, ABI, PWV, AIx, SEVR, ED, and carotid
IMT for the detection of vascular stiffness in never-
treated individuals with MetS.
Methods
Participants
From a total of 71 subjects, 12 subjects on anti-
hypertensive drugs, oral hypoglycemic agents or in-
sulin, lipid-lowering medication, or non-steroidal
anti-inflammatory drugs (aspirin) were excluded.
Fifty-nine individuals (male [M]:female [F] ratio = 35:24;
mean age, 60 ± 12 years) who visited the outpatient clinics
of the St. Mary’s Hospital between March 2012 and
August 2012 were enrolled in this study and they
were divided into the positive MetS (Mets[+]: N = 32;
M:F ratio = 19:13; mean age, 62 ± 12 years) and nega-
tive group (Mets[−]: N = 27; M:F ratio = 16:11; mean
age, 59 ± 11 years), in accordance with the 2005 Adult
Treatment Panel III criteria [2]. MetS(+) was defined
as the presence of at least three of the following five
components: (1) abdominal obesity (waist circumfer-
ence >90 cm in men and >80 cm in women); (2) tri-
glycerides ≥150 mg/dL; (3) high density lipoprotein
(HDL) cholesterol <40 mg/dL in men or <50 mg/dL
in women; (4) blood pressure ≥130/85 mmHg; and
(5) fasting plasma glucose 100 mg/dL [2].
This study was approved by the institutional review
committee of St. Mary’s Hospital. Patients were in-
formed of the investigative nature of the study and writ-
ten informed consent was obtained before enrollment
(SC 14RISI0006).
Anthropometric parameter measurement
Waist circumferences were measured using a standard-
ized tape by the same well-trained staff. The tape was
calibrated before use. The waist circumference was mea-
sured 1 inch above the umbilicus in the standing position.
Systolic blood pressure (SBP), diastolic blood pressure
(DBP), mean arterial pressure (MAP), and PP in both
brachial artery and ankles were simultaneously measured
using automated oscillometric devices (Omron HEM712C;
Omron, Tokyo, Japan) with subjects in a seated position
after resting quietly for 10 min. ABI was defined as the
ratio between the systolic pressure measured in the ankle
and that measured in the brachial artery.
Biochemical assays
Blood samples were drawn for the analysis of levels of
fasting plasma glucose, total cholesterol, triglyceride,
HDL cholesterol, low density lipoprotein cholesterol and
high-sensitivity C-reactive protein.
Framingham risk score
FRS was calculated on the basis of a number of categor-
ical variables, including age, total cholesterol level, HDL
cholesterol level, SBP, treatment for hypertension, and
cigarette smoking [1]. The 10-year risk for myocardial
infarction and CHD is estimated from total points, and
the person is categorized according to absolute 10-year
risk as indicated above [1].
Pulse wave velocity of the aorta, the arm, and the leg,
augmentation index, subendocardial viability ratio, and
ejection duration
PWV of the aorta, the arm and the leg (PWVaor,
PWVarm and PWVleg), were measured using an auto-
matic waveform analyzer (PP-1000; Hanbyul Meditech
Co., Jeonju, Korea), which provides regional PWV values
based on the results of electrocardiography, phonocardi-
ography, and then automatically recorded pulse waves
from four different arteries (carotid, femoral, radial, and
dorsalis pedis) on the left side of the body for 10 s.
PWVaor was determined as the velocity between the ca-
rotid and femoral arteries. PWVarm and PWVleg were
calculated based on the carotid-radial and the femoral-
dorsalis pedis pulse transit times, respectively.
The three main indices of cardiovascular function,
namely AIx, SEVR, and ED, were measured using
(GAON; Hanbyul Meditech Co., Jeonju, Korea), and
were defined as follows: AIx, as the ratio of the augmen-
tation pressure to PP; SEVR, as the ratio of the diastolic
pressure time integral to the systolic pressure time inte-
gral; and ED, as the duration of systolic ejection to the
total duration of a cardiac cycle. The pressures (i.e., SBP,
DBP, MAP, and PP) obtained from aortic pulse wave
referred to as central blood pressure.
Carotid Intima-media thickness
Carotid IMT was measured at the common carotid and
internal carotid arteries by B-mode ultrasound using a
15 MHz linear transducer (15 MHz transducer with
Sonos 5500; Philips, Andover, MA, USA) following a
standardized protocol. A minimum of seven measure-
ments of common carotid far (posterior) wall were
taken 20 mm proximal to the bifurcation to derive
mean carotid IMT values. For statistical analysis, mean
carotid IMT was calculated by averaging the thickness
at four sites at the far walls of both the right and left
distal common carotid arteries, two each from the right
and left arteries. The physicians who performed the
evaluation were blind to the health status and clinical
characteristics of the study participants. A single well-
trained sonographer who was blinded to clinical infor-
mation made all the measurements.
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Statistical analysis
Continuous variables are expressed as mean ± standard
deviation. Among five groups classified by the number
of MetS components, comparisons of FRS were per-
formed using the analysis of variance test. For compari-
sons between MetS(+) and MetS(−) groups, analysis for
categorical data was performed using chi-square test and
comparison for variable parameters was analyzed using
independent t-test; all analyses were conducted using
SAS statistical software ver. 9.1 (SAS Institute Inc., Cary,
NC, USA). Multivariate logistic regression analysis was
used to determine an independent tool for predicting
the probability of the presence of MetS. Statistical
significance was set at p < 0.05.
Results
Fifty-nine individuals (M:F ratio = 35:24; mean age, 60 ±
12 years) were divided into the MetS(+) (N = 32; M:F
ratio = 19:13; mean age, 62 ± 12 years) and MetS(−)
group (N = 27; M:F ratio = 16:11; mean age, 59 ± 11 years).
The baseline clinical and laboratory findings of the two
groups are summarized in Table 1.
FRS was significantly higher in the MetS(+) than
MetS(−) group (11 ± 5 vs. 14 ± 4, p < 0.01) (Fig. 1a). There
Table 1 Baseline characteristics
Variable MetS(−) group (N = 27) MetS(+) group (N = 32) p-value
Age (yr) 59 ± 11 62 ± 12 0.20
Gender (male) 16 (59.3) 19 (59.4) 0.99
Waist circumference (cm)
Male 88 ± 7 93 ± 7 0.07
Female 88 ± 14 88 ± 7 0.96
SBP (mmHg) 124 ± 20 128 ± 14 0.42
DBP (mmHg) 75 ± 7 74 ± 12 0.65
MAP (mmHg) 91 ± 12 93 ± 8 0.37
PP (mmHg) 52 ± 21 53 ± 11 0.85
Central SBP (mmHg) 114 ± 12 117 ± 11 0.47
Central DBP (mmHg) 78 ± 11 77 ± 7 0.73
Central MAP (mmHg) 93 ± 10 94 ± 8 0.77
Central PP (mmHg) 37 ± 14 40 ± 9 0.34
Ankle-brachial index 1.2 ± 0.1 1.1 ± 0.2 0.03
Fasting plasma glucose (mg/dL) 100 ± 8 120 ± 23 <0.01
Hemoglobin A1c (%) 5.8 ± 0.5 6.4 ± 1.3 0.45
Total cholesterol (mg/dL) 179 ± 38 182 ± 44 0.76
Triglyceride (mg/dL) 103 ± 37 184 ± 113 <0.01
High density lipoprotein cholesterol (mg/dL) 49 ± 13 42 ± 11 0.02
Low density lipoprotein cholesterol (mg/dL) 111 ± 34 108 ± 31 0.78
C-reactive protein (mg/L) 1.25 ± 2.09 2.15 ± 2.07 0.06
Framingham risk score 11 ± 5 14 ± 4 <0.01
Pulse wave velocity
Aorta (m/sec) 7.0 ± 1.4 8.4 ± 1.6 <0.01
Arm (m/sec) 8.0 ± 1.5 8.8 ± 1.2 0.07
Leg (m/sec) 9.4 ± 1.4 9.6 ± 1.6 0.68
Augmentation index (%) 78 ± 20 89 ± 25 0.12
Subendocardial viability ratio (%) 122 ± 21 126 ± 30 0.64
Ejection duration (ms) 352 ± 43 337 ± 43 0.30
Right mean IMT (mm) 0.81 ± 0.20 0.94 ± 0.20 0.03
Left mean IMT (mm) 0.79 ± 0.20 0.93 ± 0.20 0.03
Values are presented as mean ± standard deviation or number (%)
MetS(+) positive metabolic syndrome, MetS(−) negative metabolic syndrome, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure,
PP pulse pressure, IMT intima-media thickness
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was no significant difference in FRS among five groups
classified by the number of MetS components (0, 5 ± 13;
1, 11 ± 4; 2, 12 ± 3; 3, 13 ± 3; 4, 13 ± 5; 5, 17 ± 5; p = 0.26)
(Fig. 1b). The ABI was significantly lower in the MetS
group than in the control group (1.2 ± 0.1 vs. 1.1 ± 0.2, p =
0.03) and the PWVaor was significantly higher in the
MetS(+) than MetS(−) group (7.0 ± 1.4 m/s vs. 8.4 ± 1.6 m/
s, p < 0.01) (Fig. 2a). There was no significant difference
between the control and MetS group in PWVarm (8.0 ±
1.5 m/s vs. 8.8 ± 1.2 m/s, p = 0.07) (Fig. 2b) and PWVleg
(9.4 ± 1.4 m/s vs. 9.6 ± 1.6 m/s, p = 0.68) (Fig. 2c), respect-
ively. The right and left mean IMT was higher in the
MetS(+) than MetS(−) group (right mean IMT: 0.94 ±
0.20 mm vs. 0.81 ± 0.20 mm, p = 0.03; left mean IMT: 0.93
± 0.20 mm vs. 0.79 ± 0.20 mm, p = 0.03, respectively).
PWVaor positively correlated with FRS (r = 0.31, p = 0.03)
and PWVarm (r = 0.67, p < 0.01), respectively (Table 2).
Among the non-invasive tools, PWVaor was an independ-
ent tool for predicting the probability of the presence of
MetS (p = 0.04; odds ratio, 1.88; 95% confidence interval,
1.03 to 3.42) (Table 3). A cut-off value of PWVaor of
7.4 m/s showed a sensitivity of 66.7% and a specificity of
47.6% for predicting the probability of the presence of MetS
(Fig. 3).
Discussion
MetS is a well known accelerator of central arterial aging
and it is associated with an increased risk of cardiovas-
cular events [3–5]. The present study comparing individ-
uals with MetS and controls showed that FRS, PWVaor
and both carotid mean IMT were significantly higher.
MetS is a risk factor for the development of coronary
artery disease (CAD) and cardiovascular events. Several
studies elucidated the relationships between MetS and
FRS, which estimates 10-year risk of CHD. Based on
data from women with suspected myocardial ischemia,
Marroquin et al. [13] suggested that MetS modifies the
cardiovascular risk associated with angiographic CAD.
Specifically, MetS was found to be a predictor of 4-year
cardiovascular risk only when associated with significant
angiographic CAD. Iribarren et al. [14] reported that the
presence of MetS imparts a high risk of early-onset
clinical CAD, but the prognostic information associated
with the syndrome is not greater than the sum of its
Fig. 1 a Differences in FRS between MetS(+) and MetS(−) group and (b) among five groups classified by the number of MetS components. FRS,
Framingham risk score; MetS, metabolic syndrome
Fig. 2 Difference in PWV of the a aorta, b arm, and c leg between the MetS and control group. PWV, pulse wave velocity; MetS, metabolic
syndrome; PWVaor, pulse wave velocity of the aorta; PWVarm, pulse wave velocity of the arm; PWVleg, pulse wave velocity of the leg
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parts. In the present study, FRS was significantly higher
in the MetS than control group. Furthermore, there was
no significant difference in FRS among five groups
classified by the number of MetS components, which
warrant further investigation.
Although our results did not show a significant
difference between the control group and the MetS
group in PWVarm and PWVleg, the PWVaor was
significantly increased in the MetS group. In some stud-
ies with respect to ABI as an indicator of the presence of
PAD of the lower extremities, Vogt et al. [6] showed that
the ABI associated with mortality in elderly women, and
Zheng et al. [7] reported the association with clinical
CHD, stroke and preclinical carotid and popliteal ath-
erosclerosis in middle-aged adults. It is well established
that the PWVaor as an indicator of systemic vascular
aging, arterial compliance or stiffness, elastic modulus,
impedance, and pulse pressure amplification, which
significantly and independently associated with both
target organ damage and increased risk for cardiovascu-
lar morbidity and mortality [15–17]. Recently, Roman et al.
[18] reported that central aortic pressure more accurately
reflects loading conditions of the left ventricular myocar-
dium, coronary arteries, and cerebral vasculature and
thereby, in theory, more strongly relates to vascular disease
and outcome than does brachial pressure and suggested
the use of central blood pressure as a treatment target in
future trials.
Although a PWV >10 m/s has been suggested as a
conservative estimate of significant alterations of aortic
function according to the 2007 guidelines for the
management of arterial hypertension of the European
Society of Hypertension and of the European Society of
Cardiology [19], our investigation revealed that, among
non-invasive tools including FRS and carotid IMT,
PWVaor was an independent tool for predicting the
probability of the presence of MetS, and that a cut-off
value of PWVaor of 7.4 m/s shows a sensitivity of 66.7%
and a specificity of 47.6% for predicting the probability of
the presence of MetS. Blacher et al. [20] showed that
PWV >12.0 m/s was associated with higher cardiovascular
morbidity and mortality than PWV <9.4 m/s in patients
with end-stage renal disease. Therefore, the clinical inter-
pretation and availability of these techniques is largely
Table 2 The relationships among the non-invasive methods for the detection of vascular aging
Variable FRS PWVaor Right mean IMT
Coefficient p-value Coefficient p-value Coefficient p-value
FRS - - 0.31 0.03 0.44 <0.01
Ankle-brachial index 0.01 0.95 0.27 0.07 0.13 0.37
PWVaor (m/sec) 0.31 0.03 - - 0.27 0.11
PWVarm (m/sec) 0.08 0.61 0.67 <0.01 0.11 0.45
PWVleg (m/sec) 0.14 0.36 0.18 0.22 0.08 0.60
Augmentation index (%) 0.23 0.14 −0.08 0.61 0.32 0.04
Subendocardial viability ratio (%) −0.02 0.91 −0.11 0.48 0.17 0.28
Ejection duration (ms) −0.15 0.34 0.13 0.43 −0.08 0.64
Right mean IMT (mm) 0.44 <0.01 0.24 0.11 - -
Left mean IMT (mm) 0.45 <0.01 0.26 0.09 0.71 <0.01
FRS Framingham risk score, PWVaor pulse wave velocity of the aorta, IMT intima-media thickness, PWVarm pulse wave velocity of the arm, PWVleg pulse wave vel-
ocity of the leg
Table 3 Multivariate logistic regression analysis
Variable Adjusted odds ratio 95% Confidence interval p-value
PWV of the aorta 1.88 1.03–3.42 0.04
Ankle-brachial index 0.02 0.00–3.34 0.14
Augmentation index (%) 1.03 0.98–1.08 0.27
Subendocardial viability ratio (%) 0.99 0.96–1.03 0.69
Ejection duration (ms) 1.00 0.98–1.02 0.73
Framingham risk score 1.04 0.86–1.25 0.69
Right mean IMT 8.29 0.05–1332.23 0.42
Left mean IMT 2.08 0.02–276.36 0.77
Aortic PWV was an independent tool for predicting the probability of the presence of metabolic syndrome
PWV pulse wave velocity, IMT intima-media thickness
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limited and additional research is needed to elucidate and
explain the value of PWV.
Our results revealed that both carotid mean IMT was
higher in the MetS than control group. In several studies
on whether MetS predicts the progression of carotid
atherosclerosis, Iglseder et al. [21] reported MetS as a
stronger risk factor for early carotid atherosclerosis in
women, and Ahluwalia et al. [22] documented that MetS
is associated with subclinical atherosclerosis using the
biomarkers. Therefore, based on the present results, we
suggest that MetS can play a role in the progression of
subclinical carotid atherosclerosis.
Several limitations are considered in the present study.
One, subclinical atherosclerosis as a vascular aging can
be divided into two categories: those which increase
central arterial stiffness, and those which decrease
endothelial responsiveness. Although our results are in
concordance with PWVaor increase reflecting arterial
stiffness in the MetS group, no data are provided on
endothelial responsiveness to detect the initial progres-
sion of subclinical atherosclerosis as a vascular aging
such as results from acetylcholine stimulation tests,
flow-mediated dilation and strain gauge plethysmogra-
phy for the Mets and controls group, which warrants
further investigation via large population together
with longer-term follow-up studies are required.
Another, several studies revealed that AIx differs mark-
edly according to the difference in the study population,
such as in age, gender, health status and smoking
behavior [23–26]. Moreover, the time points (diurnal
variations) at which AIx measurements were obtained
are not reported in the present study, therefore requiring
further investigation, including SEVR, ED, PWVarm,
PWVleg as well as Aix [27, 28].
Conclusions
In conclusion, among the non-invasive tools for the
detection of vascular stiffness as a vascular aging in
never-treated individuals with MetS, the PWVaor was
an independent tool for predicting the probability of
the presence of MetS. We suggest that PWVaor, combined
with traditional tools, can play an important role as a
complementary or alternative tool for the detection of
vascular stiffness in never-treated individuals with MetS.
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